Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)

Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment

U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags

Generate Biomedicines Is Maintained at Overweight by Morgan Stanley

Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley

Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating

Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss

Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028

Generate Biomedicines Inc - Q1 Revenue $7.2 Mln

Generate Biomedicines Inc: Expects to Require Additional Capital to Support Long-Term Operations

Press Release: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Q1 FY26 net loss widens to $61.7 million; revenue falls to $7.2 million

Generate Biomedicines Initiated at Buy by HC Wainwright & Co.